Pfizer expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 after most patients treated for a form of lung cancer had no disease progression after five years.

Lung cancer drugs become a growing focus of value-based deals with health plans. By Ed Silverman Oct. 20, 2021. Reprints. Ruby Wallau for STAT. I n another bid to address the cost of prescription ...

The world's master list of recommended medicines got an update on Tuesday when the World Health Organization (WHO) published a biennial revision, adding 28 drugs including an abortion pill but ...

This is particularly true in lung cancer, where multiple drugs that target abnormalities to genes like ALK, ROS1, EGFR and now RET have reached the market. STAT+ Exclusive Story.

B y Deena Beasley. May 28 (Reuters) - The U.S. Food and Drug Administration on Friday approved an Amgen Inc AMGN.O drug for lung cancer patients with a specific mutation in a gene known as KRAS ...